New drug combo shows promise for Hard-to-Treat breast cancer in early trial
NCT ID NCT04872985
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can improve outcomes for women with stage II or III hormone receptor-positive, HER2-negative breast cancer that also has high levels of the HER4 protein. About 140 participants will receive either pyrotinib or a placebo alongside their chemo. The main goal is to see if the tumor shrinks more or disappears completely by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
Guangzhou, Guangdong, 510120, China
Conditions
Explore the condition pages connected to this study.